UA91183U - Method for treating cognitive disorders in patients with dyscirculatory encephalopathy stage ii - Google Patents
Method for treating cognitive disorders in patients with dyscirculatory encephalopathy stage iiInfo
- Publication number
- UA91183U UA91183U UAU201400467U UAU201400467U UA91183U UA 91183 U UA91183 U UA 91183U UA U201400467 U UAU201400467 U UA U201400467U UA U201400467 U UAU201400467 U UA U201400467U UA 91183 U UA91183 U UA 91183U
- Authority
- UA
- Ukraine
- Prior art keywords
- patients
- stage
- cognitive disorders
- treating cognitive
- dyscirculatory encephalopathy
- Prior art date
Links
- 208000014644 Brain disease Diseases 0.000 title abstract 2
- 208000032274 Encephalopathy Diseases 0.000 title abstract 2
- 208000010877 cognitive disease Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- AGJBKFAPBKOEGA-UHFFFAOYSA-M 2-methoxyethylmercury(1+);acetate Chemical compound COCC[Hg]OC(C)=O AGJBKFAPBKOEGA-UHFFFAOYSA-M 0.000 abstract 1
- 230000002744 anti-aggregatory effect Effects 0.000 abstract 1
- 239000003146 anticoagulant agent Substances 0.000 abstract 1
- 238000011443 conventional therapy Methods 0.000 abstract 1
- 238000001802 infusion Methods 0.000 abstract 1
- 230000001067 neuroprotector Effects 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 239000003071 vasodilator agent Substances 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The method for treating the cognitive disorders in the patients with dyscirculatory encephalopathy stage II provides for the conventional therapy comprising neuroprotectors, antiaggregants, peripheral vasodilatators and infusion therapy. In addition, Mema composition is used at a dose of 10 mg once a day for 2 months.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UAU201400467U UA91183U (en) | 2014-01-20 | 2014-01-20 | Method for treating cognitive disorders in patients with dyscirculatory encephalopathy stage ii |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UAU201400467U UA91183U (en) | 2014-01-20 | 2014-01-20 | Method for treating cognitive disorders in patients with dyscirculatory encephalopathy stage ii |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA91183U true UA91183U (en) | 2014-06-25 |
Family
ID=56282941
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAU201400467U UA91183U (en) | 2014-01-20 | 2014-01-20 | Method for treating cognitive disorders in patients with dyscirculatory encephalopathy stage ii |
Country Status (1)
| Country | Link |
|---|---|
| UA (1) | UA91183U (en) |
-
2014
- 2014-01-20 UA UAU201400467U patent/UA91183U/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021004821A (en) | Methods of cancer treatment with antagonists against pd-1 and pd-l1 in combination with radiation therapy. | |
| PH12019500521A1 (en) | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer | |
| MX2017002271A (en) | Compositions and methods for treatment of neurological disorders. | |
| MY187540A (en) | Compounds active towards bromodomains | |
| SG10201808053XA (en) | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders | |
| TW201613919A (en) | Inhibitors of Bruton's tyrosine kinase | |
| MX2017014338A (en) | Targeted selection of patients for treatment with cortistatin derivatives. | |
| MX2021009899A (en) | Administration and dosage of diaminophenothiazines. | |
| MX2021000289A (en) | Methods for treating high cardiovascular risk patients with hypercholesterolemia. | |
| MX2015012322A (en) | Use of levocetirizine and montelukast in the treatment of autoimmune disorders. | |
| MX2018010223A (en) | Combination therapy for treatment of ovarian cancer. | |
| MX379201B (en) | 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives | |
| PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
| PH12018501790A1 (en) | Treatment of patients with homozygous familial hypercholesterolemia on lipid lowering therapy | |
| PH12016502236A1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
| PH12021551138A1 (en) | Application of chidamide in combination with r-chop, and drug combination | |
| MX2017013666A (en) | Anti-fugetactic agent and immunotherapy agent combination therapy and compositions for the treatment of cancer. | |
| UA91183U (en) | Method for treating cognitive disorders in patients with dyscirculatory encephalopathy stage ii | |
| MX2018011512A (en) | Use of insulin for promoting gastric emptying. | |
| TW201613926A (en) | Inhibitors of bruton's tyrosine kinase | |
| MX2017011838A (en) | Compositions and methods for treating hepatocellular carcinoma. | |
| UA103632U (en) | Method for complex treatment of patients with anxious depression | |
| UA75277U (en) | Method for treating dystrophic diseases of retina and choroid | |
| UA93428U (en) | Method for treating high grade of lipidemia | |
| PH12016502113A1 (en) | Drug for treatment of tinnitus patients |